Human allergy

The human allergy field was the first domain of commercial activity at GENCLIS, which focused on molecular component-based diagnoses of food allergies.Here, the competitive advantages of GENCLIS stem from its capacity for innovation.

The portfolio of recombinant allergens marketed by GENCLIS is as follows:

Type of Allergy Origin Protein Name
Food Peanut
  • Ara h 1
  • Ara h 2
  • Ara h 3
  • Ara h 6
  • Ara h 7
  • Ara h 8
  • Ara h 9
Environment Mites
  • Der p 1
  • Der p 2
  • Der p 10
  • Alt a 1
Bee Venom
  • Api m 2
  • Api m 10
Wasp Venom
  • Ves v 1
  • Ves v 5

After demonstrating the importance of molecular components in the diagnosis of allergy – a diagnosis that is becoming increasingly specific – GENCLIS concluded a distribution agreement with the US Company Hycor Biomedical.
Consequently, Hycor markets GENCLIS’ allergy diagnostic tests, which use Ara h 1-2-3-6-7-8-9 peanut allergens.

GENCLIS is also directly commercializing its allergen portfolio in its entirety.
For more information, please contact us using our form.

Veterinary Allergy

Similarly to the situation in humans, lifestyle changes have increased the numbers of domesticated animals that suffer from allergies, with an estimated that 10% of cats and dogs currently suffering from food allergies (International Federation for Animal Health Europe (IFAH) Annual Report 2014).

Few veterinarians are trained in dermatology (the observable allergic manifestations are mainly cutaneous), and even fewer of them are trained in allergy. For these reasons, many veterinarians are clueless as to the diagnosis and treatment of feline or canine allergy cases.

Cyno-DIAL®, GENCLIS’ first veterinary allergy product, is based on research, in dog serum, of IgE-type antibodies directed against food. Although a negative test does not categorically eliminate a given food allergy, a positive test allows the veterinarian to select food with the least reactivity to IgE, allowing optimization of the animal’s elimination diet. GENCLIS has recently demonstrated that all so-called “hypoallergenic” dog food preparations, which are substantially hydrolyzed, do, in fact, contain nonhydrolyzed proteins that react with IgE. This discovery was the subject of an oral presentation at the 28th Annual Congress of the ESVD-ECVD (European Society and College of Veterinary Dermatology), held in September 2015. GENCLIS wishes to collaborate with manufacturers to improve the nutritional performance, while reducing the allergen content, of their products.

Therefore, Cyno-DIAL® is a tool to aid in the diagnosis of veterinary allergy. The strength of Cyno-DIAL® over competing tests is that it analyzes commercial preparations in their entirety, to select only preparations that are not recognized by dog IgEs.

Along the same lines as Cyno-DIAL®, GENCLIS developed Féli-DIAL® as a tool to aid veterinarians in the diagnosis of food allergy and selection of a diet suitable for cats. This product entered the commercial phase in early 2015. Tests for the diagnosis of allergies in horses (Equi-DIAL®) are currently under development. GENCLIS is also developing a diagnostic test for food allergies in dogs, based on the information provided by Cyno-DIAL®.

Cyno-DIAL® and Féli-DIAL® are marketed by Galileo Diagnostics, the commercial arm of GENCLIS.